Raritan, NJ, United States of America

Peter Jozef M Van Remoortere

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.. Active years: 2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Peter Jozef M Van Remoortere. Retrieved from https://idiyas.com/inventor/peter-jozef-m-van-remoortere

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


% Patents Active = 100.0


Average Co-Inventor Count = 7.0

ph-index = 1


Company Filing History:


Years Active: 2025

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: The Innovations of Peter Jozef M Van Remoortere

Introduction

Peter Jozef M Van Remoortere is an accomplished inventor based in Raritan, NJ. He has made significant contributions to the field of pharmaceuticals, particularly in the treatment of viral infections. His innovative work has led to the development of new therapeutic methods that hold promise for patients suffering from hepatitis B.

Latest Patents

Peter holds a patent for "Toll-like receptor agonists for use in the treatment of hepatitis B." This patent outlines formulations and methods utilizing a TLR-7 agonist aimed at treating hepatitis B virus infections. His work in this area is crucial for advancing treatment options and improving patient outcomes.

Career Highlights

Peter is currently associated with Chia Tai Tianqing Pharmaceutical Group Co., Ltd., where he continues to focus on innovative pharmaceutical solutions. His expertise in immunology and virology has positioned him as a key player in the development of new therapies.

Collaborations

Peter has collaborated with notable colleagues, including Sean Mark Dalziel and Ilham Smyej. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Peter Jozef M Van Remoortere's contributions to the field of pharmaceuticals, particularly through his patent on TLR-7 agonists, demonstrate his commitment to advancing medical science. His work continues to impact the treatment of hepatitis B and showcases the importance of innovation in healthcare.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…